AstraZeneca Annual Report and Form 20-F Information 2011

Consolidated Statement of Cash Flowsfor the year ended 31 DecemberCash flows from operating activitiesProfit before tax 12,367 10,977 10,807Finance income and expense 3 428 517 736Depreciation, amortisation and impairment 2,550 2,741 2,087(Increase)/decrease in trade and other receivables (1,108) 10 (256)(Increase)/decrease in inventories (256) 88 6Increase/(decrease) in trade and other payables and provisions 467 (16) 1,579Profit on disposal of subsidiary 22 (1,483) – –Other non-cash movements (597) (463) (200)Cash generated from operations 12,368 13,854 14,759Interest paid (548) (641) (639)Tax paid (3,999) (2,533) (2,381)Net cash inflow from operating activities 7,821 10,680 11,739Cash flows from investing activitiesAcquisitions of business operations 22 – (348) –Movement in short-term investments and fixed deposits 1 (2,743) (125) (1,339)Purchase of property, plant and equipment (839) (791) (962)Disposal of property, plant and equipment 102 83 138Purchase of intangible assets (458) (1,390) (624)Disposal of intangible assets – 210 269Purchase of non-current asset investments (11) (34) (31)Disposal of non-current asset investments – 5 3Net cash received on disposal of subsidiary 22 1,772 – –Interest received 171 174 113Payments made by subsidiaries to non-controlling interests (16) (10) (11)Net cash outflow from investing activities (2,022) (2,226) (2,444)Net cash inflow before financing activities 5,799 8,454 9,295Cash flows from financing activitiesProceeds from issue of share capital 409 494 135Repurchase of shares (6,015) (2,604) –Repayment of loans – (1,741) (650)Dividends paid (3,764) (3,361) (2,977)Hedge contracts relating to dividend payments 1 3 (114) (32)Movement in short-term borrowings 46 (8) (137)Net cash outflow from financing activities (9,321) (7,334) (3,661)Net (decrease)/increase in cash and cash equivalents in the period (3,522) 1,120 5,634Cash and cash equivalents at the beginning of the period 10,981 9,828 4,123Exchange rate effects (25) 33 71Cash and cash equivalents at the end of the period 13 7,434 10,981 9,828Notes2011$mRestated2010$mRestated2009$m12010 restated to reclassify $114m cash paid in hedge contracts relating to dividend payments to cash flows from financing activities (2009: $32m).Financial StatementsAstraZeneca Annual Report and Form 20-F Information 2011 Financial Statements 145